ACADIA Pharmaceuticals Inc. ROE

ROE of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2020 was -42.47% (a 6.36% increase from previous year)
  • Annual ROE for 2019 was -39.93% (a -33.69% decrease from previous year)
  • Annual ROE for 2018 was -60.22% (a -11.18% decrease from previous year)
  • Twelve month ROE ending December 30, 2020 was -42.47% (a 6.55% increase compared to previous quarter)
  • Twelve month trailing ROE decreased by -5.71% year-over-year
Trailing ROE for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
-42.47% -39.86% -42.81% -45.04%
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of ACADIA Pharmaceuticals Inc.

Most recent ROEof ACAD including historical data for past 10 years.

Interactive Chart of ROE of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -42.47%
2019 -39.93%
2018 -60.22%
2017 -67.8%
2016 -75.58%
2015 -64.58%
2014 -37.62%
2013 -28.41%
2012 -38.49%
2011 -85.82%
2010 72.43%

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.